Current prostate cancer management By Adebowale Awosika-Olumo, MD., MS., MPH, PhD, FACE
Prostate cancer management has rapidly evolved, and integrating advances in diagnostics, genomics, and personalized therapies to improve patient outcomes.
Advances in Diagnosis and Risk Stratification
Modern detection emphasizes minimizing harm and reducing overdiagnosis. Multiparametric MRI (mpMRI) has become central, improving detection of clinically significant cancers and reducing unnecessary biopsies. Prostate-specific membrane antigen (PSMA) PET/CT offers superior staging accuracy compared to conventional imaging. Risk stratification now incorporates genetic and molecular profiling, enabling more tailored management strategies(Williams et al., 2022; Rebello et al., 2021; Mohler et al., 2019).
Management of Localized Disease
For low-risk, localized prostate cancer, active surveillance is preferred to avoid overtreatment and its side effects. Surgery (radical prostatectomy) and radiation remain gold standards for intermediate and high-risk cases, with focal therapy emerging as an experimental option for select patients. Treatment choice should consider cancer severity, patient health, and preferences, as all aggressive therapies can impact urinary and sexual function(Williams et al., 2022; Rebello et al., 2021; Sebesta & Anderson, 2018; Litwin & Tan, 2017).
Management of Advanced and Metastatic Disease
Advanced prostate cancer management has shifted to include novel androgen pathway inhibitors, chemotherapy, and targeted agents. Multimodal therapy—combining androgen deprivation therapy (ADT), systemic therapy, and radiotherapy—is often recommended. For metastatic castration-resistant prostate cancer, options now include AR-targeted agents, chemotherapy, radionuclides, and PARP inhibitors for those with DNA repair mutations. PSMA-based radioligand therapy and immunotherapies are promising new additions(Sandhu et al., 2021; Williams et al., 2022; Rebello et al., 2021; Barsouk et al., 2020; Litwin & Tan, 2017).
Personalized and Emerging Therapies
Personalized medicine is increasingly important, with treatments targeting specific genomic alterations now validated. Molecular characterization of tumors guides therapy selection, and ongoing research into targeted radioisotopes, immunotherapies, and vaccines holds promise for further improving outcomes(Sandhu et al., 2021; Rebello et al., 2021; Rastogi et al., 2023).
Quality of Life and Complications
Given the long survival of many patients, managing treatment-related side effects—such as urinary, gastrointestinal, and sexual complications—is crucial. Advances in surgical and radiation techniques have reduced some risks, but long-term monitoring and supportive care remain essential(Michaelson et al., 2008; Roth et al., 2008).
Conclusion
Current prostate cancer management is highly individualized, balancing effective cancer control with quality of life. Ongoing research continues to refine diagnostic tools and expand therapeutic options, moving toward more precise and less invasive care.
References
Sandhu, S., Moore, C., Chiong, E., Beltran, H., Bristow, R., & Williams, S. (2021). Prostate cancer. The Lancet, 398, 1075-1090. https://doi.org/10.1016/S0140-6736(21)00950-8
Williams, I., McVey, A., Perera, S., O’Brien, J., Kostos, L., Chen, K., Siva, S., Azad, A., Murphy, D., Kasivisvanathan, V., Lawrentschuk, N., & Frydenberg, M. (2022). Modern paradigms for prostate cancer detection and management. The Medical Journal of Australia, 217, 424 – 433. https://doi.org/10.5694/mja2.51722
Rebello, R., Oing, C., Knudsen, K., Loeb, S., Johnson, D., Reiter, R., Gillessen, S., Van Der Kwast, T., & Bristow, R. (2021). Prostate cancer. Nature Reviews Disease Primers, 7, 1-27. https://doi.org/10.1038/s41572-020-00243-0
Barsouk, A., Padala, S., Vakiti, A., Mohammed, A., Saginala, K., Thandra, K., Rawla, P., & Barsouk, A. (2020). Epidemiology, Staging and Management of Prostate Cancer. Medical Sciences, 8. https://doi.org/10.3390/medsci8030028
Sebesta, E., & Anderson, C. (2018). The Surgical Management of Prostate Cancer.. Seminars in oncology, 44 5, 347-357. https://doi.org/10.1053/j.seminoncol.2018.01.003
Mohler, J., Antonarakis, E., Armstrong, A., D’Amico, A., Davis, B., Dorff, T., Eastham, J., Enke, C., Farrington, T., Higano, C., Horwitz, E., Hurwitz, M., Ippolito, J., Kane, C., Kuettel, M., Lang, J., McKenney, J., Netto, G., Penson, D., Plimack, E., Pow-Sang, J., Pugh, T., Richey, S., Roach, M., Rosenfeld, S., Schaeffer, E., Shabsigh, A., Small, E., Spratt, D., Srinivas, S., Tward, J., Shead, D., & Freedman-Cass, D. (2019). Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.. Journal of the National Comprehensive Cancer Network : JNCCN, 17 5, 479-505. https://doi.org/10.6004/jnccn.2019.0023
Michaelson, M., Cotter, S., Gargollo, P., Zietman, A., Dahl, D., & Smith, M. (2008). Management of Complications of Prostate Cancer Treatment. CA: A Cancer Journal for Clinicians, 58. https://doi.org/10.3322/CA.2008.0002
Litwin, M., & Tan, H. (2017). The Diagnosis and Treatment of Prostate Cancer: A Review. JAMA, 317, 2532–2542. https://doi.org/10.1001/jama.2017.7248
Roth, A., Weinberger, M., & Nelson, C. (2008). Prostate cancer: psychosocial implications and management.. Future oncology, 4 4, 561-8. https://doi.org/10.2217/14796694.4.4.561
Rastogi, I., Muralidhar, A., & McNeel, D. (2023). Vaccines as treatments for prostate cancer. Nature Reviews. Urology, 1 – 16. https://doi.org/10.1038/s41585-023-00739-w